Gracell Biotechnologies Inc's Customers Performance

Name: Gracell Biotechnologies Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

GRCL

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


GRCL's Source of Revenues		• List of GRCL Customers

for the same period Gracell Biotechnologies Inc

• List of GRCL Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Gracell Biotechnologies Inc's Comment on Sales, Marketing and Customers

News about Gracell Biotechnologies Inc Contracts

Gracell Biotechnologies Escalates Treatment for Refractory Systemic Lupus Erythematosus with NMPA and FDA Clearance for Phase 1/2 Clinical Trial

Chinese company Gracell Biotechnologies is poised to make significant strides in the treatment of refractory Systemic Lupus Erythematosus (rSLE). The biotech giant has announced that it has received clearance for IND (Investigational New Drug) application for its Phase 1/2 Clinical Trial of FasTCAR-T GC012F from both the China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA).This double clearance for IND application signifies an expansion in the clinical development of GC012F for the treatment of rSLE, not only in China but also in the United States. This conjoint approval from two of the world s most prominent drug regulatory bodies is a testament to the promis...

Game-Changing Innovations: Nitric Oxide Delivery System and Revenue Surge Propel Third Pole Therapeutics and Gracell Biotechnologies Inc Forward

:
The healthcare industry is constantly evolving, and innovative technologies are paving the way for groundbreaking treatments. In this article, we will discuss the recent developments regarding Third Pole Therapeutics Feasibility Study with the eNOfit Portable Inhaled Nitric Oxide Delivery System and provide an assessment of its impact on the company. Additionally, we will touch upon Gracell Biotechnologies Inc s revenue growth during the same period and consider its implications for the company.
Facts:
Third Pole Therapeutics recently announced the commencement of its Feasibility Study, marking a significant milestone in the development of their eNOfit Portable Inhaled Nitric Oxide Deliv...

Gracell Biotechnologies Revolutionizes Treatment for Refractory Systemic Lupus Erythematosus with Breakthrough CAR-T Therapy

Gracell Biotechnologies, a leading biotechnology company specializing in innovative cellular immunotherapies, recently received FDA clearance for its investigational new drug (IND) application for Phase 1/2 clinical trials of FasTCAR-T GC012F. This groundbreaking therapy aims to address the unmet medical needs of patients suffering from refractory systemic lupus erythematosus (SLE), a complex autoimmune disease. Gracell s dual-targeted CAR-T cell therapy shows immense promise in achieving deeper and more comprehensive depletion of disease-causing antibody secreting cells and B-cells, offering hope for those living with this debilitating condition.
The Current Landscape of SLE Treatment:
Sys...

GRCL's Stock Performance relative to it's Customers

GRCL's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Gracell Biotechnologies Inc	3,468.01	0.00	-88.08	365
SUBTOTAL	0.00	0.00	0.00	-

Sources: Gracell Biotechnologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Gracell Biotechnologies Inc’s corporate clients.
For your research, we’ve provided 9 tables on Gracell Biotechnologies Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.